MedPath

Glaucoma Study with High Intensity Focused Ultrasound

Not Applicable
Conditions
Health Condition 1: H401- Open-angle glaucoma
Registration Number
CTRI/2017/09/009740
Lead Sponsor
EYE TECH CARE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Glaucoma patients whose IOP is not well controlled with 2 or glaucoma medication

2. IOP >= 25 mmHg

3. Primary Open Angle Glaucoma (POAG) including Pigmentary Glaucoma (PG), PseudoExfoliative Glaucoma (PXFG)).

4. Any patients with previous conventional glaucoma surgery failure (such as Trabeculectomy and/or Deep Sclerectomy), or end stage glaucoma patient indicated or contraindicated for conventional filtering surgery (e.g. Trabeculectomy)

5. No previous intraocular surgery or laser treatment during the 90 days before Ultrasound Ciliary Plasty Day in the study eye.

6. Age > 18 years and < 90 years

7. Able and willing to sign the informed consent form and complete postoperative follow-up requirements.

Exclusion Criteria

1. History of cyclo-destructive procedures (cryotherapy, diode laser cyclo-destruction, and endo-photo-coagulation) in the study eye.

2. History of ciliary body surgery in the study eye

3. History of ocular or retrobulbar tumor in the study eye

4. History of vitrectomy in the study eye

5. Ocular infection within 14 days prior to the procedure of Ultrasound Ciliary Plasty (both eye)

6. Eye with implantation of glaucoma drainage device

7. Neovascular glaucoma with or without hyphema and/or vitreous haemorrhage

8. Structure abnormalities in anterior segment which lead to excessive scleral expansion or change of ciliary body location

9. Ocular disease other than glaucoma that may affect assessment of IOP (choroidal hemorrhage or detachment, lens subluxation, thyroid ophthalmopathy, and retinal detachment)

10. Any other systemic illness as per investigatorâ??s discretion which will jeopardize patientâ??s participation in the study.

11. Any patient currently participating in another drug or device study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
IOP Reduction in % (i.e 20% or more) on same or fewer IOP Lowering MedicationTimepoint: Baseline & Month 6
Secondary Outcome Measures
NameTimeMethod
Change in Mean IOP (mmHg)Timepoint: Baseline & Day-1, Day-7, Month-1, Month-2, Month-3, Month-4 & Month-6;Mean IOP Variation (%)Timepoint: Baseline & Day-1, Day-7, Month-1, Month-2, Month-3, Month-4 & Month-6;Mean number of Ocular hypotensive medicationsTimepoint: Day-1, Day-7, Month-1, Month-2, Month-3, Month-4 & Month-6;Reduction in Intraocular PressureTimepoint: Baseline & Day-1, Day-7, Month-1, Month-2, Month-3, Month-4 & Month-6 <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath